268 related articles for article (PubMed ID: 29718143)
1. The Association Between Empirical Antibiotic Treatment and Mortality in Severe Infections Caused by Carbapenem-resistant Gram-negative Bacteria: A Prospective Study.
Zak-Doron Y; Dishon Benattar Y; Pfeffer I; Daikos GL; Skiada A; Antoniadou A; Durante-Mangoni E; Andini R; Cavezza G; Leibovici L; Yahav D; Eliakim-Raz N; Carmeli Y; Nutman A; Paul M;
Clin Infect Dis; 2018 Nov; 67(12):1815-1823. PubMed ID: 29718143
[TBL] [Abstract][Full Text] [Related]
2. Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.
Dickstein Y; Lellouche J; Ben Dalak Amar M; Schwartz D; Nutman A; Daitch V; Yahav D; Leibovici L; Skiada A; Antoniadou A; Daikos GL; Andini R; Zampino R; Durante-Mangoni E; Mouton JW; Friberg LE; Dishon Benattar Y; Bitterman R; Neuberger A; Carmeli Y; Paul M;
Clin Infect Dis; 2019 Aug; 69(5):769-776. PubMed ID: 30462182
[TBL] [Abstract][Full Text] [Related]
3. Effect on 30-day mortality and duration of hospitalization of empirical antibiotic therapy in CRGNB-infected pneumonia.
Li R; Tang H; Xu H; Cui K; Li S; Shen J
Ann Clin Microbiol Antimicrob; 2021 Mar; 20(1):15. PubMed ID: 33678191
[TBL] [Abstract][Full Text] [Related]
4. Antibiotic strategies and clinical outcomes in critically ill patients with pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Liang CA; Lin YC; Lu PL; Chen HC; Chang HL; Sheu CC
Clin Microbiol Infect; 2018 Aug; 24(8):908.e1-908.e7. PubMed ID: 29108947
[TBL] [Abstract][Full Text] [Related]
5. Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.
Paul M; Daikos GL; Durante-Mangoni E; Yahav D; Carmeli Y; Benattar YD; Skiada A; Andini R; Eliakim-Raz N; Nutman A; Zusman O; Antoniadou A; Pafundi PC; Adler A; Dickstein Y; Pavleas I; Zampino R; Daitch V; Bitterman R; Zayyad H; Koppel F; Levi I; Babich T; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L
Lancet Infect Dis; 2018 Apr; 18(4):391-400. PubMed ID: 29456043
[TBL] [Abstract][Full Text] [Related]
6. The combined use of tigecycline with high-dose colistin might not be associated with higher survival in critically ill patients with bacteraemia due to carbapenem-resistant Acinetobacter baumannii.
Amat T; Gutiérrez-Pizarraya A; Machuca I; Gracia-Ahufinger I; Pérez-Nadales E; Torre-Giménez Á; Garnacho-Montero J; Cisneros JM; Torre-Cisneros J
Clin Microbiol Infect; 2018 Jun; 24(6):630-634. PubMed ID: 28970161
[TBL] [Abstract][Full Text] [Related]
7. Colistin plus meropenem for carbapenem-resistant Gram-negative infections: in vitro synergism is not associated with better clinical outcomes.
Nutman A; Lellouche J; Temkin E; Daikos G; Skiada A; Durante-Mangoni E; Dishon-Benattar Y; Bitterman R; Yahav D; Daitch V; Bernardo M; Iossa D; Zusman O; Friberg LE; Mouton JW; Theuretzbacher U; Leibovici L; Paul M; Carmeli Y;
Clin Microbiol Infect; 2020 Sep; 26(9):1185-1191. PubMed ID: 32251844
[TBL] [Abstract][Full Text] [Related]
8. Mortality burden related to infection with carbapenem-resistant Gram-negative bacteria among haematological cancer patients: a retrospective cohort study.
Andria N; Henig O; Kotler O; Domchenko A; Oren I; Zuckerman T; Ofran Y; Fraser D; Paul M
J Antimicrob Chemother; 2015 Nov; 70(11):3146-53. PubMed ID: 26209312
[TBL] [Abstract][Full Text] [Related]
9. Trimethoprim-sulfamethoxazole vs. colistin or ampicillin-sulbactam for the treatment of carbapenem-resistant Acinetobacter baumannii: A retrospective matched cohort study.
Raz-Pasteur A; Liron Y; Amir-Ronen R; Abdelgani S; Ohanyan A; Geffen Y; Paul M
J Glob Antimicrob Resist; 2019 Jun; 17():168-172. PubMed ID: 30557685
[TBL] [Abstract][Full Text] [Related]
10. The Effectiveness and Safety of High-Dose Colistin: Prospective Cohort Study.
Benattar YD; Omar M; Zusman O; Yahav D; Zak-Doron Y; Altunin S; Elbaz M; Daitch V; Granot M; Leibovici L; Paul M
Clin Infect Dis; 2016 Dec; 63(12):1605-1612. PubMed ID: 27794023
[TBL] [Abstract][Full Text] [Related]
11. Epidemiology and outcome of infections with carbapenem-resistant Gram-negative bacteria treated with polymyxin B-based combination therapy.
Crusio R; Rao S; Changawala N; Paul V; Tiu C; van Ginkel J; Chapnick E; Kupfer Y
Scand J Infect Dis; 2014 Jan; 46(1):1-8. PubMed ID: 24206450
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.
Bassetti M; Echols R; Matsunaga Y; Ariyasu M; Doi Y; Ferrer R; Lodise TP; Naas T; Niki Y; Paterson DL; Portsmouth S; Torre-Cisneros J; Toyoizumi K; Wunderink RG; Nagata TD
Lancet Infect Dis; 2021 Feb; 21(2):226-240. PubMed ID: 33058795
[TBL] [Abstract][Full Text] [Related]
13. Treatment of Carbapenem-Resistant Acinetobacter baumannii Ventilator-Associated Pneumonia: Retrospective Comparison Between Intravenous Colistin and Intravenous Ampicillin-Sulbactam.
Zalts R; Neuberger A; Hussein K; Raz-Pasteur A; Geffen Y; Mashiach T; Finkelstein R
Am J Ther; 2016; 23(1):e78-85. PubMed ID: 24263165
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of tigecycline in the treatment of infections caused by carbapenem-resistant gram-negative bacteria in pediatric liver transplant recipients: A retrospective study.
Chen F; Shen C; Pang X; Zhang Z; Deng Y; Han L; Chen X; Zhang J; Xia Q; Qian Y
Transpl Infect Dis; 2020 Feb; 22(1):e13199. PubMed ID: 31627248
[TBL] [Abstract][Full Text] [Related]
15. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
[No Abstract] [Full Text] [Related]
16. Clinical efficacy and safety of the combination of colistin plus vancomycin for the treatment of severe infections caused by carbapenem-resistant Acinetobacter baumannii.
Garnacho-Montero J; Amaya-Villar R; Gutiérrez-Pizarraya A; Espejo-Gutiérrez de Tena E; Artero-González ML; Corcia-Palomo Y; Bautista-Paloma J
Chemotherapy; 2013; 59(3):225-31. PubMed ID: 24356297
[TBL] [Abstract][Full Text] [Related]
17. Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model.
Montero A; Ariza J; Corbella X; Doménech A; Cabellos C; Ayats J; Tubau F; Borraz C; Gudiol F
J Antimicrob Chemother; 2004 Dec; 54(6):1085-91. PubMed ID: 15546972
[TBL] [Abstract][Full Text] [Related]
18. The effectiveness and nephrotoxicity of loading dose colistin combined with or without meropenem for the treatment of carbapenem-resistant A. baumannii.
Katip W; Uitrakul S; Oberdorfer P
Int J Infect Dis; 2020 Aug; 97():391-395. PubMed ID: 32502665
[TBL] [Abstract][Full Text] [Related]
19. Colistin-resistant Acinetobacter baumannii: beyond carbapenem resistance.
Qureshi ZA; Hittle LE; O'Hara JA; Rivera JI; Syed A; Shields RK; Pasculle AW; Ernst RK; Doi Y
Clin Infect Dis; 2015 May; 60(9):1295-303. PubMed ID: 25632010
[TBL] [Abstract][Full Text] [Related]
20. Antibiotic strategies and clinical outcomes for patients with carbapenem-resistant Gram-negative bacterial bloodstream infection.
Qu J; Feng C; Li H; Lv X
Int J Antimicrob Agents; 2021 Mar; 57(3):106284. PubMed ID: 33484833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
